Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

NCT01924533

CompletedPhase 3

Sponsor: AstraZeneca

Conditions: Gastric Cancer

Interventions: Olaparib, Paclitaxel, Placebo

Countries: China, Japan, South Korea, Taiwan

This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Advanced gastric cancer (including GEJ) that has progressed following first-line therapy.
* Patients must be ≥18 years of age. Age ≥20 if Japanese
* Provision of tumour sample (from either a resection or biopsy).
* At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline and following up visits.

Exclusion Criteria:

* More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting.
* Any previous treatment with a Polyadenosine 5'-diphosphoribose \[poly-(ADP-ribose)\] polymerisation (PARP) inhibitor, including olaparib.
* Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥5 years.
* Human Epidermalgrowth Factor Receptor-2 (HER2) positive patients.
Locations (57)
  • Beijing, China
  • Beijing, China
  • Beijing, China
  • Bengbu, China
  • Changchun, China
  • Changsha, China
  • Changsha, China
  • Changsha, China
  • Chengdu, China
  • Chengdu, China
  • Fuzhou, China
  • Guangzhou, China
  • Hangzhou, China
  • Hangzhou, China
  • Hangzhou, China
  • Harbin, China
  • Nanchang, China
  • Nanjing, China
  • Nanjing, China
  • Shanghai, China
  • Shanghai, China
  • Ürümqi, China
  • Wanzhou, China
  • Wuhan, China
  • Yangzhou, China
  • Zhengzhou, China
  • Chiba, Japan
  • Chūōku, Japan
  • Fukuoka, Japan
  • Kasama-shi, Japan
  • + 27 more on CT.gov